2016 International Congress

Thursday, June 23, 2016

12:00pm-1:30pm

Do predictors of good response to deep brain stimulation in primary cervical movement disorders exist?

E. Sanrey, V. Gonzalez, L. Cif, F. Cyprien, E. Borgeais, J. Perez, M. Ros, P. Coubes (Montpellier, France)

Dystonia  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Does distance walked after two minutes predict total 6 minute walk test distance in people with Parkinson’s disease?

R.P. Duncan, M.E. McNeely, G.M. Earhart (Saint Louis, MO, USA)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Does physical exercise influence the cognitive domains that predict dementia in Parkinson’s disease?

C.R.A. Silveira, E.A. Roy, B.N. Intzandt, Q.J. Almeida (Waterloo, ON, Canada)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Dopamine agonist withdrawal syndrome (DAWS) in a tertiary Parkinson’s disease center

S. Patel, X. Garcia, M.E. Mohammad, X.X. Yu, K. Vlastaris, K. O'Donnell, K. Sutton, H.H. Fernandez (Cleveland, OH, USA)

Parkinsons's Disease: Clinical Trials I

12:00pm-1:30pm

Dopamine dysregulation syndrome /DDS/ in LCIG infusion: Successful treatment without interrupting the pump therapy

A. Tóth, H. Nagy, S. Funk, A. Takáts (Budapest, Hungary)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Dopaminergic medication effect on speech in Parkinson’s disease: A kinematic study

T.E. Tong, M.L. Ng, N. Yan (Hong Kong, Hong Kong)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Dopaminergic medicines are alternative drugs for treatment of motor disorders in ischemic stroke

A. Azimov, R. Sadykov, G. Rakhimbaeva, S. Dadajonov, O. Azizova (Tashkent, Uzbekistan)

Neuropharmacology  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Dosing of abobotulinumtoxinA and muscle selection in patients with simple patterns of cervical dystonia

V.P. Misra, R. Trosch, S. Om, P. Maisonobe (London, United Kingdom)

Dystonia  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Drug safety in the pharmacotherapy of Parkinson’s disease

S. Müller-Rebstein, C. Trenkwalder, J. Ebentheuer, C. Culmsee, G. Höglinger (Kassel, Germany)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Duloxetine, a serotonin and norepinephrine reuptake inhibitor, reduces daily OFF time in Parkinson’s disease

M. Tomiyama, Y. Funamizu, T. Kon, R. Haga, T. Ueno, H. Nishijima, A. Arai, C. Suzuki, J.I. Nunomura, M. Baba (Aomori, Japan)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2